<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calabrese, Cassandra</style></author><author><style face="normal" font="default" size="100%">Rajendram, Prabalini</style></author><author><style face="normal" font="default" size="100%">Sacha, Gretchen L.</style></author><author><style face="normal" font="default" size="100%">Calabrese, Leonard</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Practical aspects of targeting IL-6 in COVID-19 disease</style></title><secondary-title><style face="normal" font="default" size="100%">Cleveland Clinic Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-05-14 12:06:27</style></date></pub-dates></dates><doi><style  face="normal" font="default" size="100%">10.3949/ccjm.87a.ccc018</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety.</style></abstract></record></records></xml>